Baricitinib for treating juvenile idiopathic arthritis in paediatric patients

Baricitinib is in clinical development for children aged 1 to 17 years with juvenile idiopathic
arthritis (JIA). JIA is defined as arthritis of unknown causes that manifests itself before the age of
16 years and persists for at least 6 weeks, while excluding other known conditions. JIA occurs
when the body’s immune system attacks its own cells and tissues. The most common symptoms
include joint swelling, pain and limited range of motion